George Yancopoulos, EVP, CSO, & President Regn Res Labs at REGENERON PHARMACEUTICALS INC (REGN), sold 900 shares at $16.99 ($16K) on 2006-01-09, disclosed to the SEC on 2006-01-11.
Scheduled sale ($16k) by EVP, CSO, & President Regn Res Labs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.87 | 7 | $118 | 0.8% |
| 2 | $16.88 | 9 | $152 | 1.0% |
| 3 | $16.91 | 30 | $507 | 3.3% |
| 4 | $16.92 | 34 | $575 | 3.7% |
| 5 | $16.98 | 30 | $509 | 3.3% |
| 6 | $16.99 | 74 |
| $1K |
| 8.1% |
| 7 | $17.00 | 11 | $187 | 1.2% |
| 8 | $17.01 | 40 | $680 | 4.4% |
| 9 | $17.02 | 74 | $1K | 8.1% |
| 10 | $17.04 | 7 | $119 | 0.8% |
| 11 | $17.14 | 45 | $771 | 4.9% |
| 12 | $17.50 | 37 | $648 | 4.2% |
| 13 | $17.52 | 16 | $280 | 1.8% |
| 14 | $17.53 | 85 | $1K | 9.6% |
| 15 | $17.54 | 22 | $386 | 2.5% |
| 16 | $17.55 | 4 | $70 | 0.5% |
| 17 | $17.56 | 103 | $2K | 11.6% |
| 18 | $17.57 | 155 | $3K | 17.5% |
| 19 | $17.58 | 95 | $2K | 10.7% |
| 20 | $17.60 | 22 | $387 | 2.5% |
| Total | $17.33 avg | 900 | $16K | 100% |
| Filing → |
| REGN | SELL | 2024-01-04 | $15.2M | — | Filing → |
| REGN | SELL | 2023-03-27 | $5.0M | — | Filing → |
| REGN | SELL | 2023-02-08 | $21.1M | — | Filing → |